Germany

Merck Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Immutep Enters Into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti

Lead Product(s): Eftilagimod Alpha,Bintrafusp Alfa

Therapeutic Area: Oncology Product Name: efti

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Immutep

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 01, 2021

Details:

The trial will study feasibility, safety & efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti or IMP321), given in combination with Merck's bintrafusp alfa (M7824), Bintrafusp alfa blocks TGF-β and PD-L1, while efti activates antigen presenting cells.

ProBioGen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Asher Biotherapeutics Contracts ProBioGen to Develop and Manufacture Their Lead Candidate

Lead Product(s): AB248

Therapeutic Area: Oncology Product Name: AB248

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Asher Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 26, 2021

Details:

ProBioGen to provide cell line development, process development and GMP manufacturing at 1000 L bioreactor scale of Asher's lead immuno-oncology candidate, AB248.